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Toward earlier diagnosis and 
treatment of rare neurological 
disorders: the value of 
coordinated care and specialist 
centers
Rare neurological diseases (RNDs) collectively exert a pub-
lic health burden in terms of their manifestations sever-
ity and the total number of people afflicted across their 
lifespan. According to the European Reference Network 
on Rare Neurological Diseases, in Europe there are 500 000 
people living with RNDs, while 60% of those affected are 
still undiagnosed due to significant phenotype and gen-
otype heterogeneity in clinical presentation and disease 
course (1). Most rare disorders are of genetic origin. For 
many patients, considerable barriers exist in terms of ac-
cess to appropriate care, delayed diagnosis, and treatment 
options. When patients are diagnosed, many are unable 
to access resources such as centers of expertise (or spe-
cialist centers), coordinated care, patient support systems, 
and effective treatment (2). Treatment of chronic RNDs has 
become increasingly multifaceted and comprises either 
disease-modifying drugs with different mechanisms of 
action, symptomatic therapies or other supportive thera-
pies, or surgical procedures such as deep brain stimulation. 
Treatment must be highly customized to the needs of the 
individual.
A systematic review conducted in 2007 proposed the fol-
lowing working definition of care coordination: “the de-
liberate organisation of patient care activities between 
two or more participants (including the patient) involved 
in a patient’s care, to facilitate the appropriate delivery of 
health care services.” This includes but is not limited to 
the use of specialist centers and specialist care coordina-
tors (3). As recommended by the EU, each member state 
by the end of 2013 needs to develop coherent strategies 
for rare diseases to ensure that patients have access to 
high-quality care (4). Strategies such as National Rare 
Disease Plans include centers of expertise or special-
ist centers on rare diseases, integrated health care admin-
istrative databases, and national registries for rare diseases. 
While some countries coordinate their approach to rare 
disease management using comprehensive specialist cen-
ters, many countries do not, either because they have not 
yet adopted this approach or are employing different strat-
egies (5). Multidisciplinary specialist centers directed to a 
particular RND may, in addition to the specialist neurolo-
gists and nurses, comprise geneticists, physiotherapists, 
occupational therapists, nutritionists, and neuropsycholo-
gists. These centers may even be cost-effective for the soci-
ety by maintaining the patient’s ability to work and reduc-
ing the costs of home help and custodial care by keeping 
people with an RND independent or minimally so.
Motivated by addressing the existing gaps in care coordi-
nation, the European Brain Council, an organization pro-
moting research on brain health and disorders in Europe, 
initiated in 2018 a two-year study on the value of early di-
agnosis and intervention, with an aim to assess the bene-
fits of coordinated care and multidisciplinary care patterns 
on patient outcomes. The project, based on the conclu-
sions of a previous EBC pan-European study (2017), The 
Value of Treatment for Brain Disorders – Policy White Paper 
(6), which called for a more seamless management of brain 
diseases, is now focusing on RNDs, aiming to include case 
studies on ataxia, dystonia, and phenylketonuria.
Ataxia and dystonia are rare movement disorders with 
broad heterogeneity, while phenylketonuria is an inher-
ited metabolic disorder occurring due to deficiency of 
the enzyme phenylalanine hydroxylase. A lack of aware-
ness and understanding of these RNDs among health 
care professionals makes their management challenging 
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and highlights the importance of guidelines for diagnosis 
and treatment. For instance, although improving time to 
reach diagnosis and early intervention for ataxia and dy-
stonia may be challenging, these improvements may ul-
timately reduce complications and disabilities. In the case 
of phenylketonuria, once a diagnosis is confirmed, usually 
through newborn screening programs, profound mental 
disability and severe neuro-psychiatric sequelae from the 
disease can be avoided by early intervention in the form 
of a “phenylalanine (Phe)-free” diet. However, this diet is 
highly restrictive, unpalatable, and can substantially affect 
patients’ and caregivers’ time and quality of life. As patients 
affected by phenylketonuria reach adolescence and adult-
hood, between 70 to 80% of them are not fully compliant 
with the prescribed diets (7). Overall, it is has not been eval-
uated so far whether better coordinated care for people 
with ataxia, dystonia, or phenylketonuria can be linked to 
measurable health gains, such as improved time to reach 
diagnosis, enhanced compliance with existing therapies, 
or better quality of life. Therefore, the aims of the ongoing 
study are to evaluate how the care for people with RNDs 
in Europe can be better coordinated and to assess the im-
pacts of this on patient care and outcomes. The case stud-
ies analysis builds on complementary research exploring 
care pathways and economic evaluation being undertak-
en as part of the project.
To evaluate different models of coordinated care for RNDs, 
the study is developing a series of qualitative and quanti-
tative benchmarks to identify treatment gaps and causal 
factors along the continuum of patient care in a pathway 
analysis. The study is also estimating the socioeconomic 
impact and health gains from specialist care centers for on-
going management of people with each disease. Data are 
taken from pre-existing surveys and diseases registries and 
previously published studies and are supplemented with 
new surveys to evaluate patient and family use and views 
of coordinated care. Coordinated care for RNDs is evalu-
ated for each case study, involving research teams com-
prising clinical specialists, experts from the European Brain 
Council, and methodological expertise from academic 
partners including University College London, University 
of Zagreb School of Medicine, and University College Dub-
lin. The research is undertaken in several European coun-
tries, depending on the availability of data, with an aim to 
capture variation in service provision. Evidence is assem-
bled across the three case studies to produce policy rec-
ommendations.
The results of this research project are to be released by 
end 2020. We hope to analyze patient views and assess 
the cost-effectiveness of specialist centers for managing 
care of people with ataxia or dystonia in several European 
countries; and the cost-effectiveness of care coordinators 
for people with phenylketonuria to reduce drop-outs, en-
courage the compliance with the Phe-free diet, and im-
prove overall health outcomes. Our aim is also to examine 
the role of national policy and programs, including Nation-
al Rare Diseases Plans on the effective implementation of 
coordinated comprehensive services directed to ataxia, 
dystonia, and phenylketonuria.
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